Characterization of CD4+ and CD8+ T Cell Subsets and Interferon Regulatory Factor 4 (IRF4) in MS Patients Treated with Fingolimod (FTY-720): A Follow-up Study

Characterization of CD4+ and CD8+ T Cell Subsets and Interferon Regulatory Factor 4 (IRF4) in MS Patients Treated with Fingolimod (FTY-720): A Follow-up Study

Fingolimod is a novel immunomodulatory drug used in patients with relapsing multiple sclerosis (MS) which reversibly inhibits egress of lymphocytes from lymph nodes. In this longitudinal study, the frequency of Interferon- gamma (IFN-γ)+, IL4+, IL17+ and IL10+ CD4+ and CD8+ T cell subsets were meas...

Full description

Bibliographic Details
Main Authors: Bahare Laribi, Mohammad Ali Sahraian, Mehdi Shekarabi, Rahimeh Emamnejad, Mohsen Marzban, Shokufeh Sadaghiani, Maryam Izad
Format: Article
Language:English
Published: Tehran University of Medical Sciences 2018-08-01
Series:Iranian Journal of Allergy, Asthma and Immunology
Subjects:
Fingolimod
IFN regulatory factor 4
Multiple sclerosis
T cell
Online Access:https://ijaai.tums.ac.ir/index.php/ijaai/article/view/1601

Internet

https://ijaai.tums.ac.ir/index.php/ijaai/article/view/1601

Similar Items